Bulletin from the Annual General Meeting of CellaVision AB (publ) held on April 26, 2011
The CellaVision Annual General Meeting (AGM) convened earlier today in Lund, April 26 2011, and resolved upon the following:
- Appropriation of profit/loss etc.
- Discharge from liability for the members of the Board of Directors and the President and CEO
- Board of Directors and remuneration
- Incentive program for senior management
- Authorization for the Board of Directors to issue shares, warrants or convertibles
- Amendment of the Articles of Association
More detailed information concerning the resolutions passed at the general meeting of shareholders is available in Swedish only.
CEO Yvonne Mårtensson's address to the meeting is available via the link below.
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB.
Tel: +46 70 535 44 44. E-mail: lars.gatenbeck@lifeequity.se
Yvonne Mårtensson, CEO, CellaVision AB.
Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2010 sales were SEK 132 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq, OMX Stockholm, Small Cap list. Read more at www.cellavision.com.